The 36-month beta value for OMGA is also noteworthy at 1.85. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for OMGA is 20.45M, and at present, short sellers hold a 29.49% of that float. The average trading volume of OMGA on November 06, 2024 was 241.30K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
OMGA) stock’s latest price update
Omega Therapeutics Inc (NASDAQ: OMGA)’s stock price has soared by 11.54 in relation to previous closing price of 1.04. Nevertheless, the company has seen a loss of -6.45% in its stock price over the last five trading days. accesswire.com reported 2024-11-05 that VANCOUVER, BC / ACCESSWIRE / November 5, 2024 / Omega Pacific Resources Inc. (CSE:OMGA)(OTCQB:OMGPF)(FSE:Q0F) (“Omega Pacific” or the “Company”) is pleased to welcome Mr. John Williamson, P.Geol.
OMGA’s Market Performance
OMGA’s stock has fallen by -6.45% in the past week, with a monthly rise of 8.41% and a quarterly drop of -24.18%. The volatility ratio for the week is 11.78% while the volatility levels for the last 30 days are 12.85% for Omega Therapeutics Inc The simple moving average for the past 20 days is 1.94% for OMGA’s stock, with a -49.34% simple moving average for the past 200 days.
Analysts’ Opinion of OMGA
Many brokerage firms have already submitted their reports for OMGA stocks, with Raymond James repeating the rating for OMGA by listing it as a “Outperform.” The predicted price for OMGA in the upcoming period, according to Raymond James is $12 based on the research report published on June 18, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see OMGA reach a price target of $15, previously predicting the price at $18. The rating they have provided for OMGA stocks is “Buy” according to the report published on May 25th, 2023.
H.C. Wainwright gave a rating of “Buy” to OMGA, setting the target price at $11 in the report published on December 08th of the previous year.
OMGA Trading at -5.77% from the 50-Day Moving Average
After a stumble in the market that brought OMGA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.59% of loss for the given period.
Volatility was left at 12.85%, however, over the last 30 days, the volatility rate increased by 11.78%, as shares surge +8.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.18% lower at present.
During the last 5 trading sessions, OMGA fell by -6.45%, which changed the moving average for the period of 200-days by -67.42% in comparison to the 20-day moving average, which settled at $1.1379. In addition, Omega Therapeutics Inc saw -61.46% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for OMGA
Current profitability levels for the company are sitting at:
- -12.77 for the present operating margin
- 0.04 for the gross margin
The net margin for Omega Therapeutics Inc stands at -12.5. The total capital return value is set at -0.57. Equity return is now at value -129.15, with -39.72 for asset returns.
Based on Omega Therapeutics Inc (OMGA), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at -2.25. The debt to equity ratio resting at 1.09. The interest coverage ratio of the stock is 49.2.
Currently, EBITDA for the company is -93.49 million with net debt to EBITDA at -1.06. When we switch over and look at the enterprise to sales, we see a ratio of 22.92. The receivables turnover for the company is 8.39for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.19.
Conclusion
In summary, Omega Therapeutics Inc (OMGA) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
